Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

CSL Finalises Agreement to Supply 51m Doses of UQ COVID-19 Vaccine Candidate to Australia

08 Oct 2020  |  09:26:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: CSL Supply Agreement for UQ Vaccine with Commonwealth

CSL announced that its subsidiary, Seqirus, has signed a final agreement (Agreement) with the Commonwealth of Australia for the supply of 51m doses of the University of Queensland-Company COVID-19 vaccine candidate (V451), should clinical trials be successful. This follows the Company's announcement of 7 September 2020 advising that a binding Heads of Agreement had been entered into with the Australian Government. The Agreement includes an up-front financial commitment from the Government to support the clinical and technical development activities that Company will need to assume in order to progress V451, and, if clinical trials are successful, also secures access to onshore production and supply of the vaccine for Australia.

Please click here for full details

See more ASX300 News Announcements